Biohaven: A Wounded Beast and a Gambler’s Hope

The SEC filings, those dry chronicles of capital’s movements, reveal the transaction. Sarissa entered the fray in the last quarter, a time when Biohaven was already listing, battered by the FDA’s dismissal of troriluzole and a string of trial results that read like epitaphs. It’s a simple truth: failure is a powerful magnet for those who profit from the misfortunes of others.








